89bio, INC Form 4 insider transactions

Ryan Martins, CFO of 89bio, Inc., disposed of 3,828 shares of common stock on February 9, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Quoc Le-Nguyen, Chief Technical Operations Officer of 89bio, Inc., sold shares to cover tax obligations arising from the vesting of restricted stock units.

Chief Medical Officer of 89bio, Inc., Harry H. Mansbach, reports disposition of shares to cover tax obligations.

RA Capital Management and related parties file Form 4, reporting changes in beneficial ownership of 89bio, Inc. stock, including the acquisition of a stock option.

Director Derek DiRocco acquired 56,400 stock options in 89bio, Inc. on February 3, 2025, according to a Form 4 filing.

Director Lota S. Zoth acquired options to purchase 56,400 shares of 89bio, Inc. common stock on February 3, 2025.

Director Martin Babler acquired stock options for 56,400 shares of 89bio, Inc. (ETNB) on February 3, 2025.

Director Steven Altschuler of 89bio, Inc. reports the acquisition of stock options for 56,400 shares of common stock.

Director Kathleen LaPorte reports the acquisition of stock options for 56,400 shares of 89bio, Inc. common stock.

Director Michael R. Hayden acquired 56,400 stock options in 89bio, Inc. on February 3, 2025, according to a Form 4 filing.

Director Charles McWherter of 89bio, Inc. acquires options to purchase 56,400 shares of common stock.

Director Edward Morrow Atkinson III acquires stock options for 56,400 shares of 89bio, Inc.

Ryan Martins, CFO of 89bio, Inc., reports acquisition of restricted stock units and stock options, as well as disposition of shares to cover tax obligations.

Quoc Le-Nguyen, Chief Technical Operations Officer of 89bio, Inc., reports acquisition of stock options and restricted stock units, as well as disposition of shares to cover tax obligations.

Rohan Palekar, CEO of 89bio, Inc., reports the acquisition and disposal of common stock, as well as the grant of stock options.

Chief Medical Officer Harry Mansbach reports acquisition of stock options and restricted stock units, along with tax-related disposals.

Chief Operating Officer Sarena Francis Willard reports acquisition and disposal of 89bio, Inc. stock and acquisition of stock options.

RA Capital Management, L.P. has acquired 5,714,285 shares of 89bio, Inc. at $8.75 per share, increasing their total holdings.

Director Charles McWherter of 89bio, Inc. engaged in multiple stock transactions, acquiring and disposing of shares on January 21st and 22nd, 2025.

An 89bio executive, Quoc Le-Nguyen, sold 10,963 shares of common stock at an average price of $6.49 per share, under a pre-arranged Rule 10b5-1 trading plan.

89bio's Chief Medical Officer, Harry H. Mansbach, acquired 95,000 shares of common stock on December 12, 2024, as part of a restricted stock unit grant.

An 89bio executive, Quoc Le-Nguyen, was granted 95,000 restricted stock units on December 12, 2024.

89bio's Chief Financial Officer, Ryan Martins, acquired 95,000 shares of common stock through restricted stock units.

89bio's Chief Executive Officer, Rohan Palekar, purchased 5,000 shares of the company's common stock at a price of $7.89 per share.

Director Charles McWherter of 89bio, Inc. purchased 10,000 shares of common stock at an average price of $8.00 per share.

89bio's Chief Executive Officer, Rohan Palekar, purchased 10,000 shares of the company's common stock at a price of $8.35 per share.

RA Capital Management and related entities acquired 3.25 million pre-funded warrants in 89bio, Inc., convertible into common stock, increasing their beneficial ownership.

Quoc Le-Nguyen, Chief Technical Operations Officer of 89bio, Inc., sold 27,955 shares of common stock at an average price of $8.12 per share under a pre-arranged 10b5-1 trading plan.

Harry H. Mansbach, Chief Medical Officer of 89bio, Inc., reports a transaction involving the withholding of shares to cover tax obligations.

Ryan Martins, CFO of 89bio, Inc., reports the disposal of 3,212 shares of common stock to cover tax obligations related to vesting restricted stock units.